Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT04658472 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

98

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Interventions

DRUG: SAR445088 (IV)
DRUG: SAR445088 (SC)

Sponsor

Bioverativ, a Sanofi company